ID: ALA4798171

Max Phase: Preclinical

Molecular Formula: C68H79F2N15O13S2

Molecular Weight: 1416.60

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  NCCCC[C@@H]1NC(=O)CCSCc2cccc(c2)CSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccc(F)cc23)NC(=O)[C@H](Cc2c[nH]c3ccc(F)cc23)NC(=O)CNC1=O

Standard InChI:  InChI=1S/C68H79F2N15O13S2/c69-42-11-15-48-46(25-42)40(29-74-48)23-51-63(93)80-52(24-41-30-75-49-16-12-43(70)26-47(41)49)64(94)82-54(28-60(89)90)66(96)81-53(27-44-31-73-36-77-44)65(95)83-55(22-37-9-13-45(86)14-10-37)68(98)85-19-4-8-57(85)67(97)84-56(61(72)91)35-100-34-39-6-3-5-38(21-39)33-99-20-17-58(87)78-50(7-1-2-18-71)62(92)76-32-59(88)79-51/h3,5-6,9-16,21,25-26,29-31,36,50-57,74-75,86H,1-2,4,7-8,17-20,22-24,27-28,32-35,71H2,(H2,72,91)(H,73,77)(H,76,92)(H,78,87)(H,79,88)(H,80,93)(H,81,96)(H,82,94)(H,83,95)(H,84,97)(H,89,90)/t50-,51-,52-,53-,54+,55-,56-,57-/m0/s1

Standard InChI Key:  KLPYFSFJVFMBJS-FSCKOFGSSA-N

Associated Targets(Human)

PCSK9/LDLR 155 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1416.60Molecular Weight (Monoisotopic): 1415.5391AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Alleyne C,Amin RP,Bhatt B,Bianchi E,Blain JC,Boyer N,Branca D,Embrey MW,Ha SN,Jette K,Johns DG,Kerekes AD,Koeplinger KA,LaPlaca D,Li N,Murphy B,Orth P,Ricardo A,Salowe S,Seyb K,Shahripour A,Stringer JR,Sun Y,Tracy R,Wu C,Xiong Y,Youm H,Zokian HJ,Tucker TJ.  (2020)  Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.,  63  (22): [PMID:33170686] [10.1021/acs.jmedchem.0c01084]

Source